PMOScope by Aufthority · Based on Lancet 2026 PMOS Consensus
A short, evidence-based screener for Polyendocrine Metabolic Ovarian Syndrome — calibrated for Malaysian women. 14 questions, about 4 minutes.
What is PMOS?
In May 2026, The Lancet ratified a new name — Polyendocrine Metabolic Ovarian Syndrome — after a 14-year global consensus. The old name implied ovarian cysts were the core problem. They are not. The real drivers are insulin resistance and androgen excess.
What this screener assesses
Irregular, infrequent, or absent periods are the most consistent hallmark of PMOS. Cycle length and pattern matter.
Excess androgen activity shows up in acne, hirsutism, and hair thinning. Asian women often score lower on standard scales even with genuine androgen excess.
Insulin resistance is present in up to 95% of PMOS women. Waist circumference, BMI, and glucose history are assessed using WHO Asia-Pacific thresholds.
Family history of PMOS, type 2 diabetes, or metabolic syndrome significantly increases risk. Ovulatory difficulty is also a core diagnostic marker.
Domain 01
Irregular or absent periods are the most consistent clinical marker of PMOS. Answer based on your typical pattern over the past 12 months.
How long is your typical menstrual cycle?
Count from the first day of one period to the first day of the next.
How many periods do you have in a year?
Have your periods become more irregular in the past 12 months?
Domain 02
PMOS involves excess androgen activity — which often manifests in the skin and hair. Asian women commonly show lower hirsutism scores even with genuine androgen excess; this screener accounts for that.
How would you describe your acne?
Jaw, chin, and back or chest acne are particularly associated with androgen excess.
Do you have excess hair growth on the face, chin, chest, or abdomen?
Adapted for Asian phenotype — even mild growth in these areas is clinically significant.
Have you experienced hair thinning or scalp hair loss?
Do you have dark skin patches on your neck, armpits, or groin?
Known as acanthosis nigricans — a visible sign of insulin resistance common in PMOS.
Domain 03
PMOS is a polyendocrine metabolic syndrome — these markers reflect insulin resistance and cardiometabolic risk. Thresholds are calibrated to WHO Asia-Pacific standards, not Western norms.
What is your waist circumference?
Measure at the narrowest point, without holding your breath.
What is your BMI?
Weight in kg divided by height in metres squared. Asian risk thresholds apply.
Have you ever been told you have elevated blood glucose, prediabetes, or insulin resistance?
How would you describe your typical diet?
Domain 04
Family history and reproductive patterns complete your risk picture. PMOS has a significant heritable component — first-degree relatives are the strongest proxy.
Does anyone in your close family have PCOS or PMOS, type 2 diabetes, or metabolic syndrome?
Have you had difficulty conceiving, or been told you have ovulation problems?
How old are you?
PMOS primarily affects women of reproductive age.
Your PMOS risk profile · Screener complete
Risk tier
—
Domain breakdown
What this means
Whether or not PMOS is confirmed, the first-line treatment is dietary and lifestyle. Reduce high-glycaemic foods — white rice, sugary drinks, white bread. Increase fibre from ulam, bayam, guava, and oats. Aim for adequate protein from ikan kembung, tauhu, and tempe. Two to three sessions of strength training per week independently improve insulin sensitivity. Free sugar below 25g daily is the WHO target — one can of sugary drink can account for nearly all of that.
About PMOS
Not just the ovaries. PMOS involves the hypothalamic-pituitary axis, adrenal glands, pancreatic insulin response, and ovarian androgen production — all dysregulated together.
75 to 95 percent of women with PMOS have insulin resistance — including lean women. Excess insulin signals the ovaries to produce more testosterone. Dietary management targets this mechanism directly.
The old name implied ovarian cysts were the defining feature. They are not. Many women with PMOS have no cysts. Many women with cysts do not have PMOS. The ovaries are downstream of the endocrine disruption.
Diagnosis requires at least two of three criteria: ovulatory dysfunction, biochemical or clinical androgen excess, and polycystic ovarian morphology. No single feature is sufficient.
This screener is for informational purposes only and does not constitute a medical diagnosis. Results should be interpreted alongside clinical history, blood investigations, and professional judgement. Based on Lancet 2026 PMOS consensus criteria (Teede et al.) and WHO Asia-Pacific anthropometric thresholds. Prevalence data from Goh 2022 (Frontiers in Endocrinology) and WHO Newsroom 2025. Scoring is weighted by clinical significance and has not been independently validated as a combined instrument in Malaysian populations. Clinical evaluation remains necessary for diagnosis.